Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Exelixis, Inc. (NASDAQ:EXEL) has been assigned an average rating of “Moderate Buy” from the twenty-three analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $44.0556.

Several analysts recently weighed in on EXEL shares. Guggenheim restated a “buy” rating and issued a $45.00 price target on shares of Exelixis in a research note on Tuesday, July 29th. Benchmark reiterated a “neutral” rating on shares of Exelixis in a research note on Monday, June 23rd. UBS Group set a $38.00 target price on Exelixis and gave the company a “neutral” rating in a research note on Wednesday, July 30th. Royal Bank Of Canada cut their target price on Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 29th. Finally, William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th.

Institutional Trading of Exelixis

Several institutional investors have recently added to or reduced their stakes in EXEL. Nuveen LLC bought a new position in shares of Exelixis during the 1st quarter valued at $123,310,000. AQR Capital Management LLC lifted its holdings in shares of Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock valued at $250,869,000 after buying an additional 2,926,884 shares during the period. Norges Bank bought a new position in shares of Exelixis during the 2nd quarter valued at $122,099,000. Qube Research & Technologies Ltd raised its holdings in Exelixis by 120.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock worth $134,306,000 after purchasing an additional 1,665,110 shares during the period. Finally, Invesco Ltd. raised its holdings in Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Up 0.3%

Exelixis stock opened at $39.14 on Friday. The company has a market capitalization of $10.54 billion, a P/E ratio of 18.82, a PEG ratio of 0.80 and a beta of 0.32. The stock’s 50 day moving average is $39.78 and its 200 day moving average is $39.65. Exelixis has a twelve month low of $25.17 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Exelixis will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.